NeoGenomics today reported preliminary, unaudited revenue of approximately $190 million for the fourth quarter of 2025, representing growth of 11% compared with Q4 2024. For the full year, the company expects to report total revenue of roughly $727 million, up 10% year-over-year. Management attributes this performance to sustained demand for its oncology test menu in the community setting, which accounts for about 80% of U.S. cancer care, and broad uptake of its latest innovations in therapy selection and minimal residual disease monitoring.

The company announced that Abhishek Jain, a life sciences finance executive with prior experience as CFO of CareDx and nearly two decades at Agilent Technologies, will join as CFO on March 2, 2026. He will succeed Jeff Sherman, who will transition to Executive Vice President on that date to oversee year-end audit completion and will remain through April 14, 2026, to ensure a smooth handover. Jain’s mandate includes strengthening financial discipline, enhancing operational efficiency and supporting NeoGenomics’ pursuit of multi-billion-dollar addressable markets in advanced cancer diagnostics.

NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and a full-service facility in Cambridge, U.K., positioning it to serve oncologists, pathologists, hospital systems and pharmaceutical partners. With one of the broadest oncology-focused testing menus on the market, the company is targeting continued double-digit revenue growth by expanding its community-based testing footprint, launching new assays for therapy selection and recurrence monitoring, and leveraging partnerships with academic centers and biopharma to drive volume and margin expansion.